According to the pathogenic changes mentioned above, drugs against AD have been developed toward anti-inflammation, anti-oxidative stress, inhibiting the production of the Aβ protein, increasing ACh synthesis or protection of cholinergic neurons, and reducing tau protein abnormality. The gene discussed is MAPT; the disease is Alzheimer disease.